Integra Lifesciences Holdings (IART) Cash & Current Investments (2009 - 2026)

Integra Lifesciences Holdings' Cash & Current Investments history runs 18 years deep, the most recent figure standing at $265.5 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 2.85% year-over-year to $265.5 million; the TTM figure through Mar 2026 stood at $265.5 million (down 2.85% YoY), while the FY2025 annual figure was $263.7 million, down 3.59% from the prior year.
• Cash & Current Investments came in at $265.5 million for Q1 2026 at Integra Lifesciences Holdings, up from $263.7 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $663.1 million in Q1 2024 to a low of $253.6 million in Q2 2025.
• A 5-year average of $344.6 million and a median of $296.9 million in 2024 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments jumped 115.74% in 2024 and slumped 58.78% in 2025, its largest moves.
• Integra Lifesciences Holdings' Cash & Current Investments stood at $456.7 million in 2022, then plunged by 32.31% to $309.1 million in 2023, then fell by 11.5% to $273.6 million in 2024, then retreated by 3.59% to $263.7 million in 2025, then climbed by 0.67% to $265.5 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $265.5 million, $263.7 million, and $267.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison